Inclusion criteria:  Metastatic castration-resistant prostate cancer; Undergoing treatment with radium-223 according to standard of care; Ability to comply with the study protocol, including completion of questionnaires on health-related quality of life; Written informed consent to the treating physician at the hospital site.  Exclusion criteria:  Prior radium-223 therapy; Impaired cognitive functioning and/or illiteracy.